Acquired by Ipsen in Aug 2022
EPZM - Epizyme, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Cambridge,
United States
Type: Equity
EPZM price evolution
EPZM
| (in millions $) | 30 Jun 2022 | 31 Mar 2022 | 31 Dec 2021 | 30 Sep 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $71.07 | $77.42 | $98.34 | $124.52 |
| Short term investments | $73.35 | $122.31 | $78.45 | $96.78 |
| Net receivables | $11.21 | $5.9 | $6.57 | $3.33 |
| Inventory | $5.54 | $4.59 | $3.22 | $1.52 |
| Total current assets | $186.84 | $228.71 | $206.04 | $247.6 |
| Long term investments | ||||
| Property, plant & equipment | $19.18 | $20.58 | $21.6 | $22.88 |
| Goodwill & intangible assets | $40.77 | $41.81 | $42.85 | $43.89 |
| Total noncurrent assets | $77.32 | $83.48 | $82.96 | $84.67 |
| Total investments | $73.35 | $122.31 | $78.45 | $96.78 |
| Total assets | $264.16 | $312.19 | $289 | $332.27 |
| Current liabilities | ||||
| Accounts payable | $5 | $7.91 | $10.27 | $9.86 |
| Deferred revenue | $0.46 | $11.95 | $11.95 | $11.95 |
| Short long term debt | $5.28 | $4.87 | $4.15 | $3.95 |
| Total current liabilities | $34.95 | $38.97 | $45.2 | $44.73 |
| Long term debt | $232.43 | $233.74 | $234.96 | $236 |
| Total noncurrent liabilities | $249.49 | $262.1 | $264.49 | $272.16 |
| Total debt | $237.71 | $238.61 | $239.11 | $239.95 |
| Total liabilities | $284.44 | $301.06 | $309.69 | $316.89 |
| Shareholders' equity | ||||
| Retained earnings | -$1331.08 | -$1295.34 | -$1239.84 | -$1189.18 |
| Other shareholder equity | -$0.25 | -$0.19 | $0 | -$0 |
| Total shareholder equity | -$20.28 | $11.12 | -$20.69 | $15.38 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $98.34 | $168.22 | $139.48 | $86.67 |
| Short term investments | $78.45 | $205.39 | $241.6 | $153.63 |
| Net receivables | $6.57 | $3.1 | $2.57 | $20.07 |
| Inventory | $3.22 | $10.46 | ||
| Total current assets | $206.04 | $405.09 | $399.18 | $272.54 |
| Long term investments | ||||
| Property, plant & equipment | $21.6 | $19.46 | $23.43 | $2.06 |
| Goodwill & intangible assets | $42.85 | $47 | ||
| Total noncurrent assets | $82.96 | $68.48 | $25.41 | $2.97 |
| Total investments | $78.45 | $205.39 | $241.6 | $153.63 |
| Total assets | $289 | $473.57 | $424.59 | $275.5 |
| Current liabilities | ||||
| Accounts payable | $10.27 | $10.16 | $8.78 | $4.78 |
| Deferred revenue | $11.95 | $3.81 | $17.11 | |
| Short long term debt | $4.15 | $4.67 | $3.04 | $0.02 |
| Total current liabilities | $45.2 | $43.4 | $34.39 | $37.83 |
| Long term debt | $234.96 | $231.08 | $42.43 | $0.05 |
| Total noncurrent liabilities | $264.49 | $245.28 | $59.07 | $4.66 |
| Total debt | $239.11 | $235.74 | $45.47 | $0.07 |
| Total liabilities | $309.69 | $288.68 | $93.45 | $42.49 |
| Shareholders' equity | ||||
| Retained earnings | -$1239.84 | -$988.71 | -$757.02 | -$586.72 |
| Other shareholder equity | $0 | $0 | $0.02 | -$0.05 |
| Total shareholder equity | -$20.69 | $184.9 | $331.14 | $233.01 |
| (in millions $) | 30 Jun 2022 | 31 Mar 2022 | 31 Dec 2021 | 30 Sep 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $27.53 | $8.7 | $11.58 | $5.2 |
| Cost of revenue | $5.17 | $2.64 | $3.15 | $2 |
| Gross Profit | $22.36 | $6.06 | $8.43 | $3.2 |
| Operating activities | ||||
| Research & development | $28.05 | $29.78 | $28.86 | $34.55 |
| Selling, general & administrative | $24.11 | $27.2 | $30.86 | $32.79 |
| Total operating expenses | $52.16 | $56.98 | $59.72 | $67.34 |
| Operating income | -$29.81 | -$50.93 | -$51.29 | -$64.14 |
| Income from continuing operations | ||||
| EBIT | -$30.35 | -$49.99 | -$44.95 | -$60.19 |
| Income tax expense | $0.03 | $0.02 | ||
| Interest expense | $5.39 | $5.48 | $5.68 | $5.64 |
| Net income | ||||
| Net income | -$35.74 | -$55.51 | -$50.65 | -$65.83 |
| Income (for common shares) | -$35.74 | -$55.51 | -$50.65 | -$65.83 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $37.43 | $15.76 | $23.8 | $21.7 |
| Cost of revenue | $10.5 | $5.07 | ||
| Gross Profit | $26.93 | $10.7 | $23.8 | $21.7 |
| Operating activities | ||||
| Research & development | $130.97 | $110.93 | $132.64 | $105.83 |
| Selling, general & administrative | $133.96 | $125.18 | $68.3 | $43.97 |
| Total operating expenses | $264.92 | $236.11 | $200.94 | $149.81 |
| Operating income | -$237.99 | -$225.42 | -$177.14 | -$128.1 |
| Income from continuing operations | ||||
| EBIT | -$228.72 | -$226.9 | -$170.24 | -$123.57 |
| Income tax expense | $0.02 | $0.11 | $0.06 | $0.06 |
| Interest expense | $22.38 | $4.68 | ||
| Net income | ||||
| Net income | -$251.12 | -$231.69 | -$170.29 | -$123.63 |
| Income (for common shares) | -$251.12 | -$231.69 | -$170.29 | -$123.63 |
| (in millions $) | 30 Jun 2022 | 31 Mar 2022 | 31 Dec 2021 | 30 Sep 2021 |
|---|---|---|---|---|
| Net income | -$35.74 | -$55.51 | -$50.65 | -$65.83 |
| Operating activities | ||||
| Depreciation | $1.28 | $1.3 | $1.33 | $1.32 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $4.45 | $5.29 | $6.88 | $6.17 |
| Total cash flows from operations | -$54.81 | -$59.19 | -$51.97 | -$42.64 |
| Investing activities | ||||
| Capital expenditures | -$0.01 | -$0.1 | -$0.17 | |
| Investments | $48.71 | -$44.18 | $18.28 | $66.81 |
| Total cash flows from investing | $48.71 | -$44.19 | $18.18 | $66.64 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $82.65 | $7.69 | $20.47 | |
| Net borrowings | ||||
| Total cash flows from financing | -$0.26 | $82.46 | $7.6 | $20.35 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$6.36 | -$20.91 | -$26.18 | $44.35 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Net income | -$251.12 | -$231.69 | -$170.29 | -$123.63 |
| Operating activities | ||||
| Depreciation | $5.25 | $3.98 | $0.84 | $1.05 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $26.79 | $27.61 | $18.02 | $12 |
| Total cash flows from operations | -$226.85 | -$206.34 | -$147.17 | -$121.6 |
| Investing activities | ||||
| Capital expenditures | -$0.49 | -$50.88 | -$0.59 | -$0.3 |
| Investments | $125.97 | $36.29 | -$84.73 | -$102.31 |
| Total cash flows from investing | $125.48 | -$14.59 | -$85.32 | -$102.61 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $31.8 | $57.86 | $225.86 | $84.34 |
| Net borrowings | $191.88 | $23.33 | -$0.13 | |
| Total cash flows from financing | $31.49 | $249.66 | $286.35 | $84.21 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$69.88 | $28.73 | $53.86 | -$139.99 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 168.37M |
| Revenue | $53.01M |
|---|---|
| EBITDA | -$180.26M |
| EBIT | -$185.49M |
| Net Income | -$207.73M |
| Revenue Q/Q | 111.59% |
| Revenue Y/Y | 62.69% |
| P/E ratio | 0.00 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 0.00 |
| Book/Share | -0.12 |
| Cash/Share | 0.42 |
| EPS | -$1.23 |
|---|---|
| ROA | -69.38% |
| ROE | 5.74K% |
| Debt/Equity | -14.97 |
|---|---|
| Net debt/EBITDA | -1.18 |
| Current ratio | 5.35 |
| Quick ratio | 5.19 |